AtriCure, Inc. (NASDAQ:ATRC) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 67.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,900 shares of the medical device company's stock after buying an additional 65,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.34% of AtriCure worth $5,009,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Blue Trust Inc. increased its holdings in shares of AtriCure by 1.8% in the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after acquiring an additional 265 shares during the period. Invesco Ltd. boosted its position in AtriCure by 0.8% during the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after purchasing an additional 334 shares in the last quarter. Perkins Capital Management Inc. grew its stake in AtriCure by 1.3% in the fourth quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after purchasing an additional 400 shares during the last quarter. Truist Financial Corp raised its holdings in AtriCure by 2.6% in the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after purchasing an additional 403 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of AtriCure by 0.9% during the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock valued at $1,569,000 after buying an additional 484 shares during the last quarter. Institutional investors own 99.11% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ATRC shares. Canaccord Genuity Group reduced their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, March 28th. JMP Securities restated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Monday, February 10th. JPMorgan Chase & Co. lowered their price target on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, March 27th. Oppenheimer upped their price objective on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Finally, Piper Sandler lifted their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $49.44.

Insider Activity at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.20% of the stock is currently owned by insiders.

AtriCure Stock Performance

NASDAQ ATRC traded down $0.91 on Friday, hitting $32.85. 77,731 shares of the company's stock traded hands, compared to its average volume of 651,898. The firm has a market capitalization of $1.61 billion, a PE ratio of -34.53 and a beta of 1.65. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The firm's 50-day moving average price is $34.42 and its two-hundred day moving average price is $34.51. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.